JS213 for Injection

DRUG2 trials

Sponsors

Shanghai Junshi Bioscience Co., Ltd.

Conditions

Advanced Lung CancerAdvanced Malignant Solid Tumors

Phase 2

A Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung Cancer

RecruitingNCT07309276

Shanghai Junshi Bioscience Co., Ltd.Advanced Lung Cancer

Start: 2026-01-23End: 2028-11-11Target: 864Updated: 2026-05-18

Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors

RecruitingNCT07480733

Shanghai Junshi Bioscience Co., Ltd.Advanced Malignant Solid Tumors

Start: 2026-04-23End: 2028-11-11Target: 410Updated: 2026-05-29